Kingsview Wealth Management’s Novo Nordisk NVO Stock Holding History

Kingsview Wealth Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348K	Buy	7,265 +1,292	+22%	+$55.5K	﹤0.01%	1121
2026 Q1	$220K	Buy	5,973 +38	+0.6%	+$1.8K	﹤0.01%	1213
2025 Q4	$302K	Buy	5,935 +653	+12%	+$33.4K	﹤0.01%	1019
2025 Q3	$293K	Buy	5,282 +16	+0.3%	+$937	﹤0.01%	972
2025 Q2	$363K	Sell	5,266 -138	-3%	-$9.39K	0.01%	880
2025 Q1	$375K	Buy	5,404 +461	+9%	+$38.1K	0.01%	815
2024 Q4	$425K	Sell	4,943 -16,449	-77%	-$1.78M	0.01%	795
2024 Q3	$2.55M	Sell	21,392 -3,908	-15%	-$521K	0.05%	313
2024 Q2	$3.61M	Buy	25,300 +4,092	+19%	+$542K	0.09%	222
2024 Q1	$2.72M	Buy	21,208 +18,942	+836%	+$2.25M	0.07%	262
2023 Q4	$234K	Sell	2,266 -378	-14%	-$37.4K	0.01%	846
2023 Q3	$240K	Buy	+2,644	New	+$233K	0.01%	830

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Kingsview Wealth Management's NVO Position: Q2 2026 in Review

Kingsview Wealth Management increased its Novo Nordisk (NVO) stake by 22% in Q2 2026, buying an estimated $55.5K and bringing the position to 7,265 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

Kingsview Wealth Management first reported a position in NVO in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.61M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Kingsview Wealth Management held 7,265 shares of Novo Nordisk worth $348K as of Q2 2026.
Kingsview Wealth Management bought 1,292 Novo Nordisk shares in Q2 2026, an estimated $55.5K.
Novo Nordisk made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1121 holding.
Kingsview Wealth Management first reported a position in Novo Nordisk in Q3 2023 and has held it in 12 quarters since.
Kingsview Wealth Management's Novo Nordisk position peaked at $3.61M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.